Document Type
Article Presentation
Original Publication Date
2023
Date of Submission
June 2023
Abstract
In this 2022 publication, Boieri et al. investigated how thymic stromal lymphopoietin (TSLP) can activate CD4+ and CD8+ T cell helper 2 (Th2) for breast cancer suppression. T cell helper 1 (Th1) cells are involved in the targeted immune response by attracting cytotoxic T lymphocytes and natural killer cells. However, Th2 cells are known to inhibit the T cell helper 1 immune response by causing allergic inflammation. Th2 activation in patients with allergic diseases conferred decreased risk of breast cancer. PyMt-tg mice were retroorbitally injected with TSLP and tumor growth and survival rate were compared between wild type mice and TSLP-PyMt-tg mice. Boieri et al. found that TSLP-PyMt-tg mice had reduced tumor growth and higher survival rates than wild type mice. TSLP-induced Th2 cells caused terminal differentiation in breast cancer cells by promoting mammary gene expression and reducing cancerous gene expression, converting tumors into lumpy structures resembling regular mammary tissue.
Rights
© The Author(s)
